Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06726889

Increasing Oral Medication Adherence for Metastatic Breast Cancer Patients

Optimizing an Intervention to Increase Oral Medication Adherence for Metastatic Breast Cancer Patients

Status
Recruiting
Phase
Study type
Observational
Enrollment
104 (estimated)
Sponsor
European Institute of Oncology · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Aim of this study is to optimize an adherence increasing intervention designed for metastatic Breast Cancer (BC) patients by applying a full factorial design in order to evaluate the optimal combination of three different intervention components.

Detailed description

Today different types of Oral Anticancer Agents (OAA) are commonly prescribed to Breast Cancer (BC) patients. Patients are reported to prefer the oral modality of administration over the intravenous one for its convenience, flexibility, and easier assumption; nonetheless, the phenomenon of medication non-adherence is well-documented. Although several interventions have been designed and tested in order to foster medication adherence among BC patients, the great majority of them were focused on adherence to endocrine therapy for early-stage BC patients, with only few exceptions involving metastatic BC patients or considering adherence to other types of OAA. The aim of this work is to optimize an adherence increasing intervention designed for metastatic BC patients. This will be achieved by applying a full factorial design in order to evaluate the optimal combination of three different intervention components (informative documentation, personalized reminders and feedback).

Conditions

Interventions

TypeNameDescription
BEHAVIORALStandard carePatient will not receive any additional interventions
BEHAVIORALDecision Support System (DSS)DSS will be used to deliver educational material through a web-page (in Italian language) accessible through a link
BEHAVIORALRemindersPersonalized reminders will be delivered to patients through a common messaging application (WhatsApp)
BEHAVIORALFeedbackFeedback message will be delivered by physician to patients, through WhatsApp, after medication diary revision

Timeline

Start date
2024-01-25
Primary completion
2025-04-01
Completion
2025-04-01
First posted
2024-12-10
Last updated
2024-12-20

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT06726889. Inclusion in this directory is not an endorsement.